¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Acute miliary tuberculosis of multiple sites"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • acute lichenoid pityriasis
    ±Þ¼ºÅ¼±¸ð¾çÀܺñ´ÃÁõ
  • acute lymphocytic leukemia
    ±Þ¼º¸²ÇÁ±¸¹éÇ÷º´
  • acute myelocytic leukemia
    ±Þ¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute necrotizing hemorrhagic encephalopathy
    ±Þ¼º±«»çÃâÇ÷³úº´(Áõ)
  • acute necrotizing retinitis
    ±Þ¼º±«»ç¸Á¸·¿°
  • acute necrotizing ulcerative gingivitis
    ±Þ¼º±«»ç±Ë¾çÀÕ¸ö¿°, ±Þ¼º±«»ç±Ë¾çÄ¡Àº¿°
  • acute nephritis
    ±Þ¼ºÄáÆÏ¿°, ±Þ¼º½ÅÀå¿°
  • acute obliterating bronchiolitis
    ±Þ¼ºÆó¼â¼¼±â°üÁö¿°
  • acute pancreatitis
    ±Þ¼ºÀÌÀÚ¿°, ±Þ¼ºÃéÀå¿°
  • acute phase reactant
    ±Þ¼º±â¹ÝÀÀ¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • acute pneumonia
    ±Þ¼ºÆó·Å
  • acute posterior ganglionitis
    ±Þ¼ºÈĽŰæÀý¿°
  • acute promyelocytic leukemia
    ±Þ¼ºÀü°ñ¼ö¼¼Æ÷¹éÇ÷º´, ±Þ¼ºÇ²°ñ¼ö¼¼Æ÷¹éÇ÷º´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • multiple serositis
    ´Ù¹ßÀ帷¿°
  • multiple stratification
    ¹µÁßÃþ
  • multiple trichoepithelioma
    ¿©·¯ÅлóÇÇÁ¾
  • multiple allelic mutation
    ¹µ¸Â¼¶µ¹¿¬º¯ÀÌ
  • multiple compressed tablet
    ´ÙÁß¾ÐÃà¾Ë¾à
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • multiple layer tablet
    ´ÙÃþ¾Ë¾à
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multiple pressure method
    ´Ù¾Ð¹ý
  • multiple sleep latency test
    ¼ö¸éÀẹ±â¹Ýº¹°Ë»ç
  • multiple subpial transection
    ´Ù¹ß¿¬¸·¹ØÀý´Ü¼ú
  • multiple suture synostosis
    ´Ù¹ßºÀÇÕÀ¯ÂøÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • acute epididymitis
    ±Þ¼º ºÎ°íȯ¿°
  • acute epididymoorchitis
    ±Þ¼º °íȯºÎ°íȯ¿°
  • acute esophagitis
    ±Þ¼º ½Äµµ¿°(¡­ãÝÔ³æú).
  • acute exacerbation
    ±Þ¼º Áõ¿À(¡­ñóç÷).
  • acute exposure
    ±Þ¼ºÇÇÆø
  • acute extradural hemorrhage
    ±Þ¼º °æ¸·¿Ü ÃâÇ÷(¡­ÌãØ¯èâõóúì).
  • acute febrile neutrophilic dermatosis ; Sweet disease
    ±Þ¼º À¯¿­ È£Áß±¸¼º ÇǺÎÁõ.
  • acute febrile neutrophilic dermatosis = Sweet disease
    ±Þ¼º À¯¿­ È£Áß±¸¼º ÇǺÎÁõ
  • acute follicular tonsillitis
    ±Þ¼º ¿©Æ÷(¼º) Æíµµ¿°
  • acute fulminating meningococcemia ; Waterhouse Friderichsen syndrome
    ±Þ¼º Àü°Ý¼º ¼ö¸·±¸±Õ±ÕÇ÷Áõ.
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
  • acute gangrenous pulpitis
    ±Þ¼º ±«Àú¼ºÄ¡¼ö¿°(ÐáàõÎÕîÅàõöÍâÐæú).
  • acute gastric dilatation
    ±Þ¼º À§È®Àå(Áõ) (¡­êÖüªíåñø).
  • acute gastritis
    ±Þ¼º À§¿°(¡­êÖæú).
  • acute gastroenteritis
    ±Þ¼º À§Àå¿° (¡­êÖ æú).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • tuberculosis of bladder
    ¹æ±¤°áÇÙ(Û¹ÎÍÌ¿ú·).
  • tuberculosis of bone
    °ñ °áÇÙ(ÍéÌ¿ú·).
  • tuberculosis of epididymis
    ºÎ°íȯ°áÇÙ(ÜùÍÂü¯Ì¿ú·).
  • tuberculosis of lymph node
    ¸²ÇÁÀý°áÇÙ(¡­Ì¿ú·).
  • tuberculosis of rib
    ´Á°ñ °áÇÙ.
  • tuberculosis of seminal vesicle
    Á¤(³¶)°áÇÙ(ïñҥ̿ú·).
  • tuberculosis of testis
    °íȯ°áÇÙ(ÍÂü¯Ì¿ú·).
  • tuberculosis of ureter
    ¿ä°ü°áÇÙ(èñη̿ú·).
  • tuberculosis ulcerosa ³ª
    ±Ë¾ç¼º(Ï÷åËàõ) °áÇÙÁõ
  • tuberculosis verrucosa cutis
    »ç¸¶±Í¾ç ÇǺΰáÇÙ
  • tuberculosis,disseminated
    ÆÄÁ¾¼º
  • tuberculosis,ghon complex
    °ïº´º¯±º
  • tuberculosis,primary
    ÀÏÂ÷¼º, ¿ø¹ß¼º
  • tuberculosis,pulmonary
    Æó
  • tuberculosis,secondary
    ÀÌÂ÷¼º, ¼Ó¹ß¼º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
Tbc Tuberculosis
  = TB, Tb
ACET Advisory Committee for the Elimination of Tuberculosis
BREASTS bronchopulmonary aspergillosis, radiotherapy, extrinsic allergic alveolitis, ankylosing spondylitis,...
CTA Canadian Tuberculosis Association; chemotactic activity; chromotropic acid; Committee on Thrombolyti...
DTCD Diploma in Tuberculosis and Chest Diseases
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
MANOVA Multiple Analysis of Variance
MAR Multiple Antibiotic Resistance
MAP Multiple Antigen Peptide
MAP Multiple Antigenic Peptide
MCS Multiple Chemical Sensitivities
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute bacterial endocarditis
    ±Þ¼º ¼¼±Õ¼º ½É³»¸·¿°
  • acute bacterial meningitis
    ±Þ¼º ¼¼±Õ¼º ³ú¸·¿°
  • acute bacterial sialadenitis
    ±Þ¼º ¼¼±Õ¼º Ÿ¾×¼±¿°
  • acute bleeding
    ±Þ¼º ÃâÇ÷
  • acute brain disorder
    ±Þ¼º ³úÀå¾Ö
  • acute bronchitis
    ±Þ¼º ±â°üÁö¿°
    ´Ü±â°£¿¡ ´Ù¼Ò ÁßÁõ °æ°ú¸¦ ÃëÇÏ´Â ±â°üÁöÀÇ ¿°ÁõÀ¸·Î, ¿øÀÎÀº °¨±â¿¡ °É¸®°Å³ª Àڱؼº ¹°ÁúÀÇ ÈíÀÎÀ̳ª ±Þ¼º °¨¿° µîÀ̸ç, ¹ß¿­, È£Èí°ï¶õ, ±âÁú ¹× ±âħ¿¡ µ¿¹ÝÇÏ´Â ÈäºÎ µÎÅë µîÀ» Ư¡À¸·Î ÇÑ´Ù.
  • acute bulbar polioencephalitis
    ±Þ¼º ¿¬¼öȸ¹é³ú¿°
  • acute candidosis
    ±Þ¼º ĵµð´ÙÁõ
    Ä­µð´Ù¼ÓÀÇ ±ÕÀ¸·Î ÀÎÇÑ ±Þ¼º°¨¿°º´.
  • acute care bed
    ÀÀ±Þ Ä¡·á º´»ó
  • acute catarrhal laryngitis
    ±Þ¼º īŸ¸£ Èĵο°, ±Þ¼º īŸ¸£¼º Èĵο°
  • acute cellular rejecion
    ±Þ¼º ¼¼Æ÷¼º °ÅºÎ
    ÀϹÝÀûÀ¸·Î ÀÌ½Ä ÈÄ ¼ö °³¿ù ³»¿¡ ¹ß»ýÇϸç Ç÷û Å©·¹¾ÆÆ¼´ÑÄ¡°¡ »ó½ÂÇÏ°í ±Þ¼º ½ÅºÎÀüÀÇ ÀÓ»óÁõ»óÀ» µ¿¹ÝÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â °£Áú³» ´ÜÇÙ¼¼Æ÷ ħÀ±ÀÌ ¸Å¿ì °­ÇÏ°Ô ³ªÅ¸³ª¸ç, ºÎÁ¾ ¹× °æµµÀÇ °£Áú³» ÃâÇ÷À» º¸À̴µ¥ »ç¶÷ÀÇ °æ¿ì ´ÜÇÙ¼¼Æ÷´Â ÁÖ·Î Áß°£ Å©±â¿Í ÀÛÀº ¸²ÇÁ±¸·Î ±¸¼ºµÇ¾î ÀÖ°í dzºÎÇÑ È£¿°±â¼º ¼¼Æ÷Áú°ú ¼öÆ÷¼º ÇÙÀ» °¡Áø ¼Ò¼öÀÇ ÇüÁú¼¼Æ÷ ħÀ±µµ º¼ ¼ö ÀÖ´Ù.
  • acute cerebral anemia
    ±Þ¼º ³ú ºóÇ÷
  • acute cholecystitis
    ±Þ¼º ´ã³¶¿°
    ¼¼±Õ °¨¿°¿¡ ÀÇÇØ »ý±â°í °æ·Î´Â »óÇ༺
  • acute closed lock
    ±Þ¼º Æó±¸¼º °úµÎ°É¸²
    µ¿Åë¾øÀÌ 25~30mm
  • acute coalescent mastoiditis
    ±Þ¼º À¶ÇÕ À¯µ¹±â¿°, ±Þ¼º À¶ÇÕ¼º À¯µ¹±â¿°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
multiple alcohol An alcohol containing more than one OH group.
(05 Mar 2000)
multiple amputation Amputation of two or more limbs or parts of limbs performed at the same operation.
(05 Mar 2000)
multiple anchorage Anchorage in which more than one type of resistance unit is utilised.
Synonym: reinforced anchorage.
(05 Mar 2000)
multiple birth offspring The offspring in multiple pregnancies (pregnancy, multiple): twins, triplets, quadruplets, quintuplets, etc.
(12 Dec 1998)
multiple carboxylase deficiency Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase.
(12 Dec 1998)
multiple chemical sensitivity An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61)
(12 Dec 1998)
multiple cloning site Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments.
(18 Nov 1997)
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á